CoMentis' Series E Round

CoMentis raised a round of funding on March 18, 2016. Investors include Sanderling Ventures.

CoMentis is focused on developing drugs to treat various central nervous system (CNS) disorders such as Alzheimer's disease and schizophrenia. The company covers the research and development spectrum …

Articles about CoMentis' Series E Round: